Kinetics of hydralazine elimination
- PMID: 862310
- DOI: 10.1002/cpt1977216715
Kinetics of hydralazine elimination
Abstract
Hydralazine was given orally in single doses of 10, 25, and 50 mg to 2 slow-acetylating subjects, while 2 rapid-acetylating subjects also received 100- and 150-mg doses on different occasions. Administration of the 50-mg dose to the subjects who were slow acetylators and the 150-mg dose to those who were rapid acetylators caused a disproportionately large increase in the amount of unchanged drug appearing in the systemic circulation as judged from the increases in the ratios of areas under concentration-time curves (AUC) to dose. A modification of the gas-liquid chromatographic hydralazine assay allowed the simultaneous determination of hydralazine and its acetylated metabolite, 3-methyl-s-triazolo-3,4,a-phthalazine (MTP), in serum. It was found that the disproportionately large increases in the AUC/dose ratio of hydralazine upon intake of 50 or 150-mg doses by the slow and rapid-acetylating subjects, respectively, were paralleled by a decrease in the ratio AUCMTP/AUChydralazine during a 6-hr observation period. It is concluded that the acetylation of hydralazine in man is a capacity-limited process.
Similar articles
-
Gas chromatographic method for the simultaneous determination of hydralazine and its acetylated metabolite in serum using a nitrogen-selective detector.J Chromatogr. 1980 Aug 8;183(2):159-66. doi: 10.1016/s0378-4347(00)81689-8. J Chromatogr. 1980. PMID: 7400274
-
Studies on hydralazine. III. Bioavailability of hydralazine in man.Eur J Clin Pharmacol. 1976;10(6):395-401. doi: 10.1007/BF00563075. Eur J Clin Pharmacol. 1976. PMID: 1001354
-
Polymorphic acetylation of hydralazine.Clin Pharmacol Ther. 1980 Sep;28(3):350-5. doi: 10.1038/clpt.1980.173. Clin Pharmacol Ther. 1980. PMID: 7408395
-
Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man.J Chromatogr. 1980 Mar 14;181(3-4):427-40. doi: 10.1016/s0378-4347(00)81145-7. J Chromatogr. 1980. PMID: 7391156
-
Genetically determined variability in acetylation and oxidation. Therapeutic implications.Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003. Drugs. 1985. PMID: 2859977 Review.
Cited by
-
Clinical pharmacokinetics of hydralazine.Clin Pharmacokinet. 1982 May-Jun;7(3):185-205. doi: 10.2165/00003088-198207030-00001. Clin Pharmacokinet. 1982. PMID: 7047041 Review. No abstract available.
-
Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.J Clin Pharmacol. 2019 Dec;59(12):1678-1689. doi: 10.1002/jcph.1477. Epub 2019 Jun 30. J Clin Pharmacol. 2019. PMID: 31257615 Free PMC article.
-
Clinical pharmacokinetics of hydrallazine.Clin Pharmacokinet. 1977 Sep-Oct;2(5):317-29. doi: 10.2165/00003088-197702050-00001. Clin Pharmacokinet. 1977. PMID: 913002 No abstract available.
-
Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues.Ann Transl Med. 2021 Apr;9(8):730. doi: 10.21037/atm-2020-ubih-05. Ann Transl Med. 2021. PMID: 33987428 Free PMC article. Review.
-
Effects of concurrent administration of other substrates of N-acetyltransferase on dapsone acetylation.Br J Clin Pharmacol. 1981 Jul;12(1):83-6. doi: 10.1111/j.1365-2125.1981.tb01860.x. Br J Clin Pharmacol. 1981. PMID: 7248142 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources